Conditions: Glaucoma, Open-Angle Ocular Hypertension
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 376
Healthy volunteers: no

Brief summary:
This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.

Detailed description:

Arms:
arm 1: 0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.

Interventions: intervention 1: 0.15% Brimonidine Tartrate
Intervention descriptions: intervention 1: 0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.

Protocol document: